VIP (Vasoactive Intestinal Peptide) – User Manual & Research Protocol Guide

VIP (Vasoactive Intestinal Peptide) is a neuropeptide studied for its role in vasodilation, immune modulation, and cellular signaling. In research settings, it is used to investigate inflammatory pathways, smooth muscle relaxation, pulmonary signaling, and neuroimmune communication.

Research Applications

Neuroimmune signaling studies
Inflammatory response modulation models
Pulmonary and vascular function research
Smooth muscle relaxation physiology
Cellular communication and peptide receptor research

Disclaimer: VIP is for research and experimental use only and is not FDA-approved for therapeutic use.

Lyophilized Powder

Freeze-dried VIP intended for reconstitution prior to use in research settings.

Reconstituted Solution

Prepared liquid form used as a research solution after addition of the appropriate solvent.

VIP is studied for its ability to:

• Bind to VPAC receptors involved in cellular signaling
• Promote vasodilation in experimental vascular models
• Modulate inflammatory cytokine activity
• Influence smooth muscle relaxation pathways
• Support neuroimmune communication signaling

Observed effects are derived from preclinical and investigational research settings.

Subcutaneous (SC) – Standard Research Model

Typical research protocols use 50–200 µg per administration, generally 1–2 times daily, often in receptor signaling studies.

Intranasal Research Model

Dosing is protocol-dependent with variable frequency, used as an investigational delivery method.

Short-Course Research

Some studies use 50–100 µg daily for limited-duration protocols.

Important

There is no approved human dosage. The ranges above reflect commonly cited research patterns only.

Initiation

A 1-week phase used for initial response observation at the start of the study.

Active Study Phase

Typically 2–8 weeks, focused on evaluating signaling pathways and related outcomes.

Rest Period

A 2–4 week interval between study cycles to allow recovery and system reset.

Note

Cycle duration may vary depending on research design and study endpoints.

Supplies

Sterile bacteriostatic water
Sterile syringe
Alcohol swabs

General Procedure

1. Clean vial stopper with alcohol.
2. Add bacteriostatic water to desired concentration.
   Example: 1 mg vial + 1 mL → 1 mg/mL
3. Swirl gently to dissolve (do not shake).
4. Refrigerate at 2–8°C after reconstitution.
5. Use within 2–4 weeks or per protocol.

Maintain sterile handling technique
Document preparation concentration and date
Follow institutional research standards
Rotate administration sites in injectable models

Lyophilized Powder

Store in a cool, dry environment to maintain stability, with a shelf life of up to 12 months.

Reconstituted Solution

Keep refrigerated at 2–8°C and use within 2–4 weeks after preparation.

Protection Guidelines

Protect from light, heat, and contamination to preserve quality.

Safety Note

Discard the solution if it becomes cloudy or discolored, as this may indicate degradation or contamination.

• Research use only
• Not for therapeutic application
• Human safety outside controlled
• research is not established
• Potential research observations:
• injection-site irritation
• Maintain sterile technique
• Keep out of reach of unauthorized personnel

Peptide: VIP (Vasoactive Intestinal Peptide)Category: Neuroimmune & Vascular ResearchDelivery: Injectable or intranasal research modelTypical Investigational Range: 50–200 µg per administrationCycle: 2–8 week research protocolsStorage: Refrigerated after reconstitution